Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cryptolepine is a natural indoloquinoline alkaloid found predominantly in the roots of Cryptolepis sanguinolenta and other plants[1][2]. It exhibits a wide range of pharmacological activities, including antimalarial, anticancer, anti-inflammatory, antidiabetic, antiprotozoal, antibacterial, antifungal, anti-hyperglycemic, antipyretic, antimuscarinic, and acetylcholinesterase/butyrylcholinesterase inhibitory effects[1][2][3][4][6][7]. Cryptolepine operates via multiple mechanisms: it intercalates into DNA (particularly between cytosine-guanine base pairs), inhibits topoisomerase II, suppresses DNA synthesis[1][3][8], and blocks key oncogenic and inflammatory pathways such as p53, STAT3, and PI3K/Akt[3]. It has promising activity against malaria, several protozoal and bacterial infections, as well as a variety of cancers, including breast cancer[3][6]. Additionally, it functions as a multi-target cholinesterase inhibitor, relevant for neurodegenerative diseases such as Alzheimer’s disease[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cryptolepine.